SRx Health Solutions (SRXH) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
29 Jun, 2026Platform overview and strategy
AI-enabled platform invests in high-conviction operating companies, strategic assets, and technology-driven opportunities.
Proprietary AI platform and QAM engine drive decision-making, risk management, and capital allocation.
Value compounded through disciplined capital allocation, operational excellence, and innovation.
Multi-asset design includes core BTC and ETH holdings, options strategies, and traditional assets.
Leadership team combines expertise in consumer brands, finance, and quantitative asset management.
EMJX platform and performance
EMJX employs a dual value creation model: NAV growth via strategic asset acquisition and option yield reinvestment.
QAM engine uses macro indicators, machine learning, and Bayesian logic for dynamic asset allocation and hedging.
Three pillars: multi-asset design, AI-driven timing/hedging, and trust/narrative premium with strong social presence.
Back-tested results show EMJX outperforms single-asset strategies, smoothing volatility and generating yield.
Institutional-grade risk management includes scenario stress testing, dynamic position sizing, and strict collateral discipline.
Halo pet food brand
Halo is a premium, all-natural pet food brand with a strong e-commerce presence and asset-light manufacturing.
$6.3M revenue in 1H'26, driven by recurring sales on Amazon and Chewy.
Targets high-income, emotionally invested pet owners; plans brick-and-mortar expansion in 2027.
Pet food market projected to grow from $132.4B in 2025 to $247.7B in 2035, driven by premiumization and sustainability.
Growth strategy includes margin improvement, brand unification, innovation, and omnichannel expansion.
Latest events from SRx Health Solutions
- Merger creates a global health and wellness platform with strong growth and expansion plans.SRXH
2024 Sidoti Virtual Micro-Cap Conference8 Jul 2026 - Net sales up 23% to $3.4M, 37% margin, $6.4M net loss, and liquidity at $20.5M.SRXH
Q2 202615 May 2026 - $2.8M sales, $13.1M cash, $18M digital assets, and EMJX deal drive 2026 growth outlook.SRXH
Q1 20263 Mar 2026 - Q2 2024 net income surged 190% on margin gains and a $3.6M debt extinguishment gain.SRXH
Q2 20241 Feb 2026 - $125M all-stock deal expands into veterinary medicine with strong growth and synergy prospects.SRXH
M&A Announcement19 Jan 2026 - Returned to profitability with 33% sales growth and strong Asia-Pacific and margin gains.SRXH
Q3 202414 Jan 2026 - Q4 revenue up 26%, gross margin at 36%, and net loss nearly break-even for the year.SRXH
Q4 202426 Dec 2025 - All proposals, including the SRx acquisition and name change, were approved by stockholders.SRXH
EGM 202524 Dec 2025 - Pet wellness firm pivots to Halo brand, registers 187M+ shares amid ongoing losses and dilution risk.SRXH
Registration Filing23 Dec 2025